Jim Cramer's top 10 things to watch in the stock market Thursday

Markets look cautiously mixed with an Iran tension-driven pullback in the prior session as S&P 500/stock-specific catalysts dominate today. SK Hynix’s Nasdaq listing is set after a $28B fundraise (U.S. listing >7x oversubscribed), but biotech headlines are a drag: AstraZeneca is down ~8% after its Wainua late-stage trial failed (Ionis -~20%). On the positives, Meta plans to put AI chips into production in September (+compute capacity), and PepsiCo posts a mixed quarter (slight earnings miss but strong revenue beat), with major premarket reactions across upgrades/downgrades (e.g., Five Below -2% premarket; Truist upgrades Solstice post a 24% deal-related plunge).

Analysis

The tape is telling you liquidity is still working, but issuance is becoming the marginal headwind: a heavily subscribed foreign tech listing is fine in isolation, yet a cluster of equity and convert supply tends to cap breadth over the next 1-3 months by soaking up risk appetite. That matters most for high-duration AI names like META, where the market is increasingly trading on incremental free-cash-flow dilution rather than the size of the opportunity set. If the chip rollout translates into a compute monetization story, the stock can re-rate again; if not, every capex step-up becomes a multiple problem.

On the consumer side, this is a quality-vs-volume regime. PEP’s margin pressure is the cleaner tell: branded packaged goods are still passing through cost inflation, but only the strongest categories can protect mix, so snack exposure looks more fragile than beverage. FIVE is the better expression of lower-end consumer resilience if traffic holds, while WMT/COST continue to pressure mid-tier discretionary share; the risk is that the same bargain-seeking that helps FIVE also compresses basket economics for everyone else.

The more interesting dislocations are in the cyclicals and biotech: ODFL looks like a multi-month beneficiary if freight volumes keep inflecting because operating leverage is finally turning after a long trough, while AVAV may be over-earning the scarcity premium after a sharp run and a crowded short squeeze. In healthcare, the AZN/IONS read-through is less about one drug and more about the market demanding higher proof before assigning platform value to late-stage RNA assets; that should keep a structural valuation premium on cash-generative names like LLY and JNJ. Contrarianly, the pullbacks are not random—they reflect a market that is rewarding near-term cash conversion and punishing stories with delayed monetization.

Key Decisions for Investors

• Add META on weakness over the next 1-2 weeks; best risk/reward is if shares hold the pre-news gap and management reiterates a path to monetize AI capacity. Falsify if capex rises without incremental revenue or margin leverage over the next two quarters.
• Go long ODFL for a 1-3 month freight-cycle rebound; use any broad market dip to enter. The setup is a classic operating-leverage trade, with downside if industrial volumes roll over or pricing discipline breaks.
• Short or buy put spreads on AVAV into post-downgrade strength; keep size modest because squeeze risk is real after the recent run. Thesis breaks if backlog converts cleanly and defense spending broadens beyond the current flat patch.
• Stay underweight IONS on rallies versus quality healthcare longs like LLY/JNJ. The failed trial lowers confidence in the platform monetization timeline; thesis reverses only if a new program or partnering event restores revenue visibility.
• Treat FIVE as a conditional long, not a chase: initiate only if the next comp print confirms traffic stability and gross margin recovery. If the lower-end consumer weakens, this becomes a value trap quickly.